Custom adeno-associated virus capsids: The next generation of recombinant vectors with novel tropism

Human Gene Therapy

Volumn 16, Issue 4, 2005, Pages 408-416

  Muzyczka, Nicholas ^a   Warrington Jr , Kenneth H ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; PARVOVIRUS VECTOR; RECOMBINANT DNA; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; AMINO ACID SEQUENCE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; IMMUNOGENICITY; IN VIVO STUDY; LIFE CYCLE; MOSAICISM; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS VIRULENCE;

ANIMALS; CAPSID; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; MOSAICISM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC; TROPISM; VIRAL STRUCTURAL PROTEINS; VIRUS CULTIVATION;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 18444391257     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.408     Document Type: Review

References (47)

1. 2 antibody. Nat. Biotechnol. 17, 181-186.
2. BECERRA, S.P., ROSE, J.A., HARDY, M., BAROUDY, B.M., and ANDERSON, C.W. (1985). Direct mapping of adeno-associated virus capsid proteins B and C: A possible ACG initiation codon. Proc. Natl. Acad. Sci. U.S.A. 82, 7919-7923.
3. BECERRA, S.P., KOCZOT, F., FABISCH, P., and ROSE, J.A. (1988). Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J. Virol. 62, 2745-2754.
4. BOWLES, D.E., RABINOWITZ, J.E., and SAMULSKI, R.J. (2003). Marker rescue of adeno-associated virus (AAV) capsid mutants: A novel approach for chimeric AAV production. J. Virol. 77, 423-432.
5. BUNING, H., RIED, M.U., PERABO, L., GERNER, P.M., HUTTNER, N.A., ENSSLE, J., and HALLEK, M. (2003). Receptor targeting of adeno-associated virus vectors. Gene Ther. 10, 1142-1151.
6. CARTER, P.J., and SAMULSKI, R.J. (2000). Adeno-associated viral vectors as gene delivery vehicles. Int. J. Mol. Med. 6, 17-27.
7. CASSINOTTI, P., WEITZ, M., and TRATSCHIN, J.D. (1988). Organization of the adeno-associated virus (AAV) capsid gene: Mapping of a minor spliced mRNA coding for virus capsid protein 1. Virology 167, 176-184.
8. GAO, G.P., ALVIRA, M.R., WANG, L., CALCEDO, R., JOHNSTON, J., and WILSON, J.M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859.
9. GAO, G., ALVIRA, M.R., SOMANATHAN, S., LU, Y., VANDENBERGHE, L.H., RUX, J.J., CALCEDO, R., SANMIGUEL, J., ABBAS, Z., and WILSON, J.M. (2003). Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. U.S.A. 100, 6081-6086.
10. GAO, G., VANDENBERGHE, L.H., ALVIRA, M.R., LU, Y., CALCEDO, R., ZHOU, X., and WILSON, J.M. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388.
11. GIGOUT, L., REBOLLO, P., CLEMENT, N., WARRINGTON, K.H., Jr., MUZYCZKA, N., LINDEN, R.M., and WEBER, T. (2005). Altering AAV tropism with mosaic viral capsids. Mol. Ther. (In press).
12. GIROD, A., RIED, M., WOBUS, C., LAHM, H., LEIKE, K., KLEINSCHMIDT, J., DELEAGE, G., and HALLEK, M. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052-1056.
13. GIROD, A., WOBUS, C.E., ZADORI, Z., RIED, M., LEIKE, K., TIJSSEN, P., KLEINSCHMIDT, J.A., and HALLEK, M. (2002). The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 83, 973-978.
14. GRIFMAN, M., TREPEL, M., SPEECE, P., GILBERT, L.B., ARAP, W., PASQUALINI, R., and WEITZMAN, M.D. (2001). Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964-975.
15. HAUCK, B., CHEN, L., and XIAO, W. (2003). Generation and characterization of chimeric recombinant AAV vectors. Mol. Ther. 7, 419-425.
16. JANIK, J.E., HUSTON, M.M., and ROSE, J.A. (1984). Adeno-associated virus proteins: Origin of the capsid components. J. Virol. 52, 591-597.
17. KASHIWAKURA, Y., TAMAYOSE, K., IWABUCHI, K., HIRAI, Y., SHIMADA, T., MATSUMOTO, K., NAKAMURA, T., WATANABE, M., OSHIMI, K., and DAIDA, H. (2005). Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 79, 609-614.
18. KERN, A., SCHMIDT, K., LEDER, C., MULLER, O.J., WOBUS, C.E., BETTINGER, K., VON DER LIETH, C.W., KING, J.A., and KLEINSCHMIDT, J.A. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072-11081.
19. KRONENBERG, S., KLEINSCHMIDT, J.A., and BOTTCHER, B. (2001). Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2, 997-1002.
20. LOILER, S.A., CONLON, T.J., SONG, S., TANG, Q., WARRINGTON, K.H., AGARWAL, A., KAPTURCZAK, M., LI, C., RICORDI, C., ATKINSON, M.A., MUZYCZKA, N., and FLOTTE, T.R. (2003). Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther. 10, 1551-1558.
21. MCPHERSON, R.A., and ROSE, J.A. (1983). Structural proteins of adenovirus-associated virus: Subspecies and their relatedness. J. Virol. 46, 523-529.
22. MONAHAN, P.E., and SAMULSKI, R.J. (2000a). AAV vectors: Is clinical success on the horizon? Gene Ther. 7, 24-30.
23. MONAHAN, P.E., and SAMULSKI, R.J. (2000b). Adeno-associated virus vectors for gene therapy: More pros than cons? Mol. Med. Today 6, 433-440.
24. MULLER, O.J., KAUL, F., WEITZMAN, M.D., PASQUALINI, R., ARAP, W., KLEINSCHMIDT, J.A., and TREPEL, M. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040-1046.
25. MURALIDHAR, S., BECERRA, S.P., and ROSE, J.A. (1994). Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: Effects on regulation of synthesis and biological activity. J. Virol. 68, 170-176.
26. NICKLIN, S.A., and BAKER, A.H. (2002). Tropism-modified adeno-viral and adeno-associated viral vectors for gene therapy. Curr. Gene Ther. 2, 273-293.
27. NICKLIN, S.A., BUENING, H., DISHART, K.L., DE ALWIS, M., GIROD, A., HACKER, U., THRASHER, A.J., ALI, R.R., HALLEK, M., and BAKER, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174-181.
28. OPIE, S.R., WARRINGTON, K.H., Jr., AGBANDJE-MCKENNA, M., ZOLOTUKHIN, S., and MUZYCZKA, N. (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995-7006.
29. PERABO, L., BUNING, H., KOFLER, D.M., RIED, M.U., GIROD, A., WENDTNER, C.M., ENSSLE, J., and HALLEK, M. (2003). In vitro selection of viral vectors with modified tropism: The adeno-associated virus display. Mol. Ther. 8, 151-157.
30. PONNAZHAGAN, S., MAHENDRA, G., KUMAR, S., THOMPSON, J.A., and CASTILLAS, M., Jr. (2002). Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J. Virol. 76, 12900-12907.
31. QING, K., MAH, C., HANSEN, J., ZHOU, S., DWARKI, V., and SRIVASTAVA, A. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5, 71-77.
32. RABINOWITZ, J.E., and SAMULSKI, R.J. (2000). Building a better vector: The manipulation of AAV virions. Virology 278, 301-308.
33. RABINOWITZ, J.E., XIAO, W., and SAMULSKI, R.J. (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265, 274-285.
34. RABINOWITZ, J.E., BOWLES, D.E., FAUST, S.M., LEDFORD, J.G., CUNNINGHAM, S.E., and SAMULSKI, R.J. (2004). Cross-dressing the virion: The transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol. 78, 4421-4432.
35. RIED, M.U., GIROD, A., LEIKE, K., BUNING, H., and HALLEK, M. (2002). Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J. Virol. 76, 4559-4566.
36. SHI, W., and BARTLETT, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515-525.
37. SHI, W., ARNOLD, G.S., and BARTLETT, J.S. (2001). Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697-1711.
38. SUMMERFORD, C., and SAMULSKI, R.J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445.
39. 5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82.
40. TREMPE, J.P., and CARTER, B.J. (1988). Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein. J. Virol. 62, 3356-3363.
41. WARRINGTON, K.H., Jr., GORBATYUK, O.S., HARRISON, J.K., OPIE, S.R., ZOLOTUKHIN, S., and MUZYCZKA, N. (2004). Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol. 78, 6595-6609.
42. WHITE, S.J., NICKLIN, S.A., BUNING, H., BROSNAN, M.J., LEIKE, K., PAPADAKIS, E.D., HALLEK, M., and BAKER, A.H. (2004). Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109, 513-519.
43. WORK, L.M., NICKLIN, S.A., BRAIN, N.J., DISHART, K.L., VON SEGGERN, D.J., HALLEK, M., BUNING, H., and BAKER, A.H. (2004). Development of efficient viral vectors selective for vascular smooth muscle cells. Mol. Ther. 9, 198-208.
44. WU, P., XIAO, W., CONLON, T., HUGHES, J., AGBANDJE-MCKENNA, M., FERKOL, T., FLOTTE, T., and MUZYCZKA, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647.
45. XIE, Q., BU, W., BHATIA, S., HARE, J., SOMASUNDARAM, T., AZZI, A., and CHAPMAN, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 10405-10410.
46. YANG, Q., MAMOUNAS, M., YU, G., KENNEDY, S., LEAKER, B., MERSON, J., WONG-STAAL, F., YU, M., and BARBER, J.R. (1998). Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther. 9, 1929-1937.
47. ZHANG, H.G., XIE, J., DMITRIEV, I., KASHENTSEVA, E., CURIEL, D.T., HSU, H.C., and MOUNTZ, J.D. (2002). Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production. J. Virol. 76, 12023-12031.